Vaxxinity, Inc. Overview
Pro stress-test →Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia. Founded in 2019, the company seeks to disrupt the monoclonal antibody space by making therapeutics more affordable and accessible.
Strategic Profile
Pro stress-test →The platform is anchored in proprietary UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies. The company aims to disrupt the treatment paradigm for chronic diseases dominated by drugs with prohibitive costs and cumbersome administration, leveraging its synthetic peptide vaccine platform to enable a new class of therapeutics that will improve quality, convenience, and access.
Competitive Landscape
Pro stress-test →Vaxxinity's top competitors include Alector, Dynavax, and HOOKIPA Pharma. The company competes in the immunotherapeutic vaccine space against established monoclonal antibody manufacturers and other peptide-based vaccine developers, positioning itself as a lower-cost alternative. Its differentiation lies in multitope synthetic peptide design enabling multiple target antigens in a single formulation.
Industry Context
Vaxxinity, Inc. operates in Immunotherapeutic vaccines for chronic disease.
Key facts
Founded: 2019 · Headquarters: Dallas, US · Employees: 20 (as of April 2026) · Revenue: N/A · Market cap: N/A